Nucleic acid-based marker approaches to urologic cancers

Robert W. Veltri, Danil V. Makarov

Research output: Contribution to journalReview articlepeer-review

17 Scopus citations


There are numerous molecular modifications known to occur in cancer. New nucleic acid-based biomarkers provide a unique approach to patient management in urologic oncology. Malignant transformation of a normal cell requires a series of epigenetic and genetic changes or "hits." Epigenetics produced by deoxyribonucleic acid methylation, adding a methyl group to the fifth position of cytosine within CpG dinucleotides, are important players in deoxyribonucleic acid repair, genome instability, and regulation of chromatin structure. Genetic alterations in cancer can include mutations, chromosome deletions, insertions, amplifications, and translocations. In addition, the modifications of telomeres are critical to the maintenance of chromatin structure, transcription, and cell function in cancer. We review only nucleic acid-based molecular biomarkers in urologic oncology that can assist the clinician in establishing the diagnosis of disease, or that can predict the behavior of the disease or the patient's survival.

Original languageEnglish (US)
Pages (from-to)510-527
Number of pages18
JournalUrologic Oncology: Seminars and Original Investigations
Issue number6
StatePublished - Nov 2006


  • Biomarkers
  • Epigenetic signatures
  • Genetic signatures
  • Molecular markers
  • Nucleic acid markers
  • Oncology
  • Urology

ASJC Scopus subject areas

  • Oncology
  • Urology


Dive into the research topics of 'Nucleic acid-based marker approaches to urologic cancers'. Together they form a unique fingerprint.

Cite this